Breastfeeding in women with systemic lupus erythematosus: results from a Norwegian quality register

Table 5 Differences in breastfeeding and non-breastfeeding mothers with SLE 12 months after delivery

	N	Breastfeeding N = 27	N	Non-breastfeeding N = 63	p-value^a
Age ≥ 35 years, (%)	27	22.2	63	28.6	0.61
BMI (kg/m2), mean (SD)	25	24.5 (4.0)	40	23.9 (5.1)	0.34
Overweight (≥ 25 kg/m2), (%)	25	44.0	40	33.3	0.43
Working status (full- or parttime), (%)	27	40.7	45	48.9	0.63
VAS scores (0–100), median (IQR)	23		33
Pain		15 (1–61)		18 (4–26)	0.57
Fatigue		33 (7–73)		30(10–51)	0.75
Global score		13 (1–24)		25 (10–41)	0.06
Inflammatory active disease* (%)	21	9.5	28	21.4	0.44
CRP value (mg/L), mean (SD)	26	2.50 (4.5)	42	2.48 (3.1)	0.18
Regular physical activity** (%)	18	38.9	32	53.1	0.39
Medications, n (%)	27		63
HCQ		22 (81.5)		45 (71.4)	0.43
sDMARD***		10 (37.0)		20 (31.7)	0.63
bDMARD****		0		1 (1.6)	-

SD standard deviation, BMI bodymass index, CRP c-reactive protein, VAS visual analog scale, IQR interquartile range, HCQ hydroxychloroquine, s-DMARD synthetic disease modifying anti-rheumatic drugs, bDMARDs biologic disease modifying anti-rheumatic drugs
^*measured by LAI-P/SLEDAI. Active disease: ≥ 2,2 (LAI-P) or > 6 (SLEDAI)
^**at least once weekly
^***sDMARDs included azathioprine, methotrexate, sulphasalazine and mycophenolate mofetil
^****bDMARDs included belimumab, TNF-inhibitors and interleukin inhibitors
^agroup comparisons were performed using Fisher´s exact test for categorical variables and independent samples t-test for continuous, normally distributed variables. For ordinal and continuous, non-normally distributed data Mann Whitney U test was performed

ISSN: 1746-4358